FDA begins hearing on COX-2 drugs

Share this article:
The FDA kicked off the first of three days of advisory committee hearings today probing the safety of COX-2 drugs.
Steven Galson, acting director of the FDA's Center for Drug Evaluation and Research, promised prompt action, saying the agency will make a decision in the next few weeks based on the committees' recommendations. The FDA is not required to accept such recommendations, but generally does.
Galson also reminded the group that COX-2s are important painkillers used widely by people in chronic pain and that it is important to balance the drugs' risks with their benefits.
The committees will hear from government officials, physicians, researchers and the public before voting on recommendations for COX-2s.
The FDA has been criticized for being slow to recognize problems with COX-2s after clinical studies showed an increased risk of heart attack and stroke in users of Merck's Vioxx and Pfizer's Celebrex and Bextra. 
Merck voluntarily withdrew Vioxx in September. Celebrex and Bextra remain on the market.
Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.